Our work provided important insights into the immune determinants of poor prognosis in HBV+ DLBCL, highlighting the pivotal role of CD4+ T cell dysfunction in driving disease progression and adverse clinical outcomes. Here, CD4 is linked to diffuse large B-cell lymphoma.